المؤلفون: Hjæresen, Simone, Benedikz, Eirikur, Sejbaek, Tobias, Axelsson, Markus, Novakova, Lenka, Zhang, Mengliang, Lycke, Jan, Illes, Zsolt, Fex-Svenningsen, Åsa

المصدر: Hjæresen , S , Benedikz , E , Sejbaek , T , Axelsson , M , Novakova , L , Zhang , M , Lycke , J , Illes , Z & Fex-Svenningsen , Å 2024 , ' High temperature requirement A1 and macrophage migration inhibitory factor in the cerebrospinal fluid; a potential marker of conversion from relapsing-remitting to secondary progressive multiple sclerosis ' , Journal of the Neurological Sciences , vol. 457 , 122888 . https://doi.org/10.1016/j.jns.2024.122888Test

مصطلحات موضوعية: Biomarker, HTRA1, MIF, Multiple sclerosis, Secondary progression

الوصف: BACKGROUND: Predictive and prognostic biomarkers for multiple sclerosis (MS) remain a significant gap in MS diagnosis and treatment monitoring. Currently, there are no timely markers to diagnose the transition to secondary progressive MS (SPMS). OBJECTIVE: This study aims to evaluate the discriminatory potential of the High temperature requirement serine protease (HTRA1)/Macrophage migration inhibitory factor (MIF) cerebrospinal fluid (CSF) ratio in distinguishing relapsing-remitting (RRMS) patients from SPMS patients. METHODS: The MIF and HTRA1 CSF levels were determined using ELISA in healthy controls (n = 23), RRMS patients before (n = 22) and after 1 year of dimethyl fumarate treatment (n = 11), as well as in SPMS patients before (n = 11) and after 2 years of mitoxantrone treatment (n = 7). The ability of the HTRA1/MIF ratio to discriminate the different groups was determined using receiver operating curve (ROC) analyses. RESULTS: The ratio was significantly increased in treatment naïve RRMS patients while decreased again in SPMS patients at baseline. Systemic administrated disease modifying treatment (DMT) only significantly affected the ratio in RRMS patients. ROC analysis demonstrated that the ratio could discriminate treatment naïve RRMS patients from SPMS patients with 91% sensitivity and 100% specificity. CONCLUSION: The HTRA1/MIF ratio is a strong candidate as a MS biomarker for SPMS conversion.

وصف الملف: application/pdf

العلاقة: https://portal.findresearcher.sdu.dk/da/publications/55ba6a8a-0215-4d74-9371-2789809ea2f3Test

الإتاحة: https://doi.org/10.1016/j.jns.2024.122888Test
https://portal.findresearcher.sdu.dk/da/publications/55ba6a8a-0215-4d74-9371-2789809ea2f3Test
https://findresearcher.sdu.dk/ws/files/256833644/1-s2.0-S0022510X24000236-main.pdfTest

المؤلفون: Hjæresen, Simone, Benedikz, Eirikur, Sejbaek, Tobias, Axelsson, Markus, Novakova, Lenka, Zhang, Mengliang, Lycke, Jan, Illes, Zsolt, Fex-Svenningsen, Åsa

المصدر: Journal of the Neurological Sciences ; volume 457, page 122888 ; ISSN 0022-510X

مصطلحات موضوعية: Neurology (clinical), Neurology

الإتاحة: https://doi.org/10.1016/j.jns.2024.122888Test
https://api.elsevier.com/content/article/PII:S0022510X24000236?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S0022510X24000236?httpAccept=text/plainTest

المؤلفون: Roos, Izanne, Hughes, Stella, McDonnell, Gavin, Malpas, Charles B., Sharmin, Sifat, Boz, Cavit, Alroughani, Raed, Ozakbas, Serkan, Buzzard, Katherine, Skibina, Olga, van der Walt, Anneke, Butzkueven, Helmut, Lechner-Scott, Jeannette, Kuhle, Jens, Terzi, Murat, Laureys, Guy, Van Hijfte, Liesbeth, John, Nevin, Grammond, Pierre, Grand’Maison, Francois, Soysal, Aysun, Jensen, Ana Voldsgaard, Rasmussen, Peter Vestergaard, Svendsen, Kristina Bacher, Barzinji, Ismael, Nielsen, Helle Hvilsted, Sejbæk, Tobias, Prakash, Sivagini, Stilund, Morten Leif Munding, Weglewski, Arkadiusz, Issa, Nadia Mubder, Kant, Matthias, Sellebjerg, Finn, Gray, Orla, Magyari, Melinda, Kalincik, Tomas, Cabrera-Gomez, Jose Antonio, Roullet, Etienne, Zwanikken, Cees, Den braber-Moerland, Leontien, Barnett, Michael, Hodgkinson, Suzanne, Garber, Justin, Slee, Mark, McCombe, Pamela, Taylor, Bruce, MacDonell, Richard, Massey, Jennifer, Van Pesch, Vincent, Decoo, Danny, Willekens, Barbara, Fragoso, Yara, Prevost, Julie, Prat, Alexandre, Girard, Marc, Larochelle, Catherine, Oh, Jiwon, Lalive, Patrice, Gobbi, Claudio, Horakova, Dana, Havrdova, Eva, Ampapa, Radek, Izquierdo, Guillermo, Eichau, Sara, Sanchez-Menoyo, Jose L., Ramo-Tello, Cristina, Blanco, Yolanda, Saiz, Albert, Besora, Sarah, Shaygannejad, Vahid, Cartechini, Elisabetta, Diamanti, Matteo, Amato, Maria Pia, Spitaleri, Daniele, Patti, Francesco, Chisari, Clara, D'Amico, Emanuele, Salvatore, Lo Fermo, Yamout, Bassem, Khoury, Samia J., Al-Asmi, Abdullah, Jose Sa, Maria, Al-Harbi, Talal, Karabudak, Rana, Turkoglu, Recai, Kilpatrick, Trevor, King, John, Nguyen, Ai-Lan, Dwyer, Chris, Monif, Mastura, Taylor, Lisa, Baker, Josephine, MSBase Study GroupDanish MS Registry Study Group, missing

المصدر: JAMA NEUROLOGY ; ISSN: 2168-6149 ; ISSN: 2168-6157

مصطلحات موضوعية: Medicine and Health Sciences, Neurology (clinical)

الوصف: IMPORTANCE Ocrelizumab, a humanized monoclonal antibody targeted against CD20+ B cells, reduces the frequency of relapses by 46% and disability worsening by 40% compared with interferon beta 1a in relapsing-remitting multiple sclerosis (MS). Rituximab, a chimeric monoclonal anti-CD20 agent, is often prescribed as an off-label alternative to ocrelizumab. OBJECTIVE To evaluate whether the effectiveness of rituximab is noninferior to ocrelizumab in relapsing-remitting MS. DESIGN, SETTING, AND PARTICIPANTS This was an observational cohort study conducted between January 2015 and March 2021. Patients were included in the treatment group for the duration of study therapy and were recruited from the MSBase registry and Danish MS Registry (DMSR). Included patients had a history of relapsing-remitting MS treated with ocrelizumab or rituximab, a minimum 6 months of follow-up, and sufficient data to calculate the propensity score. Patients with comparable baseline characteristics were 1:6 matched with propensity score on age, sex, MS duration, disability (Expanded Disability Status Scale), prior relapse rate, prior therapy, disease activity (relapses, disability accumulation, or both), magnetic resonance imaging lesion burden (missing values imputed), and country. EXPOSURE Treatment with ocrelizumab or rituximab after 2015. MAIN OUTCOMES AND MEASURES Noninferiority comparison of annualized rate of relapses (ARRs), with a prespecified noninferiority margin of 1.63 rate ratio. Secondary end points were relapse and 6-month confirmed disability accumulation in pairwise-censored groups. RESULTS Of the 6027 patients with MS who were treated with ocrelizumab or rituximab, a total of 1613 (mean [SD] age; 42.0 [10.8] years; 1089 female [68%]) fulfilled the inclusion criteria and were included in the analysis (898 MSBase, 715 DMSR). A total of 710 patients treated with ocrelizumab (414 MSBase, 296 DMSR) were matched with 186 patients treated with rituximab (110 MSBase, 76 DMSR). Over a pairwise censored mean (SD) follow-up of 1.4 ...

وصف الملف: application/pdf

العلاقة: https://biblio.ugent.be/publication/01H3V7X4ZJC9NSDGKQ4YZ8KWSSTest; http://hdl.handle.net/1854/LU-01H3V7X4ZJC9NSDGKQ4YZ8KWSSTest; http://doi.org/10.1001/jamaneurol.2023.1625Test; https://biblio.ugent.be/publication/01H3V7X4ZJC9NSDGKQ4YZ8KWSS/file/01H3V85T18SG00E3996891NRJXTest

الإتاحة: https://doi.org/10.1001/jamaneurol.2023.1625Test
https://biblio.ugent.be/publication/01H3V7X4ZJC9NSDGKQ4YZ8KWSSTest
http://hdl.handle.net/1854/LU-01H3V7X4ZJC9NSDGKQ4YZ8KWSSTest
https://biblio.ugent.be/publication/01H3V7X4ZJC9NSDGKQ4YZ8KWSS/file/01H3V85T18SG00E3996891NRJXTest

المؤلفون: Novak, Frederik, Bajwa, Hamza Mahmood, Coia, John Eugenio, Nilsson, Anna Christine, Nielsen, Christian, Holm, Dorte K, Østergaard, Kamilla, Hvidt, Mathilde Vilhelmine Miller, Byg, Keld-Erik, Johansen, Isik S, Mittl, Kristen, Rowles, William, Zamvil, Scott S, Bove, Riley, Sabatino, Joseph J, Sejbaek, Tobias

المصدر: Novak , F , Bajwa , H M , Coia , J E , Nilsson , A C , Nielsen , C , Holm , D K , Østergaard , K , Hvidt , M V M , Byg , K-E , Johansen , I S , Mittl , K , Rowles , W , Zamvil , S S , Bove , R , Sabatino , J J & Sejbaek , T 2023 , ' Low protection from breakthrough SARS-CoV-2 infection and mild disease course in ocrelizumab-treated patients with multiple sclerosis after three mRNA vaccine doses ' , Journal ....

الوصف: BACKGROUND: Our study investigated the rate of breakthrough SARS-CoV-2 infection and clinical outcomes in a cohort of multiple sclerosis (MS) patients who were treated with the anti-CD20 monoclonal antibody (Ab), ocrelizumab, before first, second and third BNT162b2 mRNA vaccinations. To correlate clinical outcomes with the humoral and cellular response. METHODS: The study was a prospective non-randomised controlled multicentre trial observational study. Participants with a diagnosis of MS who were treated for at least 12 months with ocrelizumab prior to the first BNT162b2 mRNA vaccination were prospectively followed up from January 2021 to June 2022. RESULTS: Out of 54 participants, 32 (59.3%) developed a positive SARS-CoV-2 PCR test in the study period. Mild infection was observed in all infected participants. After the third vaccination, the non-infected participants had higher mean Ab levels compared to the infected participants (54.3 binding antibody unit (BAU)/mL vs 26.5 BAU/mL, p=0.030). The difference in reactivity between spike-specific CD4+ and CD8+ T lymphocytes in the two groups was not significant. CONCLUSION AND RELEVANCE: The study results demonstrate rates of 59% in breakthrough infections after the third SARS-CoV-2 mRNA vaccination in ocrelizumab-treated patients with MS, without resulting in critical disease courses. These findings suggest the need for continuous development of prophylactic treatments when proved important in the protection of severe breakthrough infection.

وصف الملف: application/pdf

العلاقة: https://portal.findresearcher.sdu.dk/da/publications/7f7d46b7-0b27-42ee-a0d8-b825f16ad1d2Test

الإتاحة: https://doi.org/10.1136/jnnp-2022-330757Test
https://portal.findresearcher.sdu.dk/da/publications/7f7d46b7-0b27-42ee-a0d8-b825f16ad1d2Test
https://findresearcher.sdu.dk/ws/files/234063659/jnnp_2022_330757.full.pdfTest

المؤلفون: Elkjaer, Maria L., Lohse, Rikke M., Burton, Mark, Mendoza, Jason P., Thomassen, Mads, Sejbaek, Tobias, Illes, Zsolt

المصدر: Elkjaer , M L , Lohse , R M , Burton , M , Mendoza , J P , Thomassen , M , Sejbaek , T & Illes , Z 2023 , ' Whole blood miRNAs in relapsing MS patients treated with dimethyl fumarate in the phase 4 TREMEND trial ' , Journal of Neuroimmunology , vol. 381 , 578145 . https://doi.org/10.1016/j.jneuroim.2023.578145Test

مصطلحات موضوعية: Dimethyl-fumarate (DMF), miRNA, Multiple sclerosis, Neurofilament light chain (NFL), NF-kB

الوصف: We investigated the impact of dimethyl fumarate (DMF), an oral therapy for relapsing multiple sclerosis (MS), on blood microRNA (miRNA) signatures and neurofilament light (NFL) levels. DMF normalized miR-660-5p and modulated various miRNAs associated with the NF-kB pathway. These alterations reached a peak 4–7 months after treatment. Notably, particular miRNAs correlated with high or low NFL levels, implying their potential role as markers of treatment efficacy. Our findings broaden the understanding of DMF's immunomodulatory effects and may aid in predicting treatment responses.

وصف الملف: application/pdf

العلاقة: https://portal.findresearcher.sdu.dk/da/publications/5cd52b43-883e-49a8-9139-0e6a8cf942caTest

الإتاحة: https://doi.org/10.1016/j.jneuroim.2023.578145Test
https://portal.findresearcher.sdu.dk/da/publications/5cd52b43-883e-49a8-9139-0e6a8cf942caTest
https://findresearcher.sdu.dk/ws/files/238095545/1_s2.0_S0165572823001315_main.pdfTest

المؤلفون: Jonasson, Elise, Antulov, Ronald, Trøllund Pedersen, Per, Sejbæk, Tobias

المصدر: Jonasson , E , Antulov , R , Trøllund Pedersen , P & Sejbæk , T 2023 , ' Progressive multifocal leukoencephalopathy in a patient with multiple myeloma : a case report and analysis of the FDA adverse event reporting system ' , Frontiers in Neurology , vol. 14 , 1098930 . https://doi.org/10.3389/fneur.2023.1098930Test

مصطلحات موضوعية: case report, FAERS, immunosuppression, multiple myeloma, PML, progressive multifocal leukoencephalopathy

الوصف: This paper demonstrates a case of progressive multifocal leukoencephalopathy (PML) in a patient with multiple myeloma (MM) treated with nine different MM therapies. This case report contributes to the already published 16 cases of PML in patients with MM. Additionally, this paper presents an analysis of cases from the United States Food and Drug Administration Adverse Event Report System database (n = 117) with a description of demographics and MM-specific therapies. Patients with MM, that developed PML, were treated with immunomodulatory drugs (97%), alkylating agents (52%), and/or proteasome inhibitors (49%). Prior to PML diagnosis, 72% of patients received two or more MM therapies. These results indicate that PML in MM is underreported and could be related to treatment with multiple immunosuppressive therapies rather than MM as a disease itself. Physicians should be aware of potential PML in the late stage of heavily treated MM patients.

وصف الملف: application/pdf

العلاقة: https://portal.findresearcher.sdu.dk/da/publications/282c02ed-19e3-453b-ae84-703b4d1d562fTest

الإتاحة: https://doi.org/10.3389/fneur.2023.1098930Test
https://portal.findresearcher.sdu.dk/da/publications/282c02ed-19e3-453b-ae84-703b4d1d562fTest
https://findresearcher.sdu.dk/ws/files/231650178/Open_Access_Version.pdfTest

المؤلفون: Myrdal, Eva, Danielsen, Tatiana Viktoria, Sejbaek, Tobias

المصدر: Myrdal , E , Danielsen , T V & Sejbaek , T 2023 , ' Reply to editorial letter on Limited value of a patient-reported triage algorithm in an outpatient epilepsy clinic ' , Danish Medical Journal , vol. 70 , no. 6 , A300004 . < https://ugeskriftet.dk/dmj/reply-editorial-letter-limited-value-patient-reported-triage-algorithm-outpatient-epilepsyTest >

مصطلحات موضوعية: Algorithms, Epilepsy, Humans, Outpatients, Patient Reported Outcome Measures, Triage

الوصف: This is a reply to the letter to the editor regarding the article "Limited value of a patient-reported triage algorithm in an outpatient epilepsy clinic" Dan Med J 2022;69(7):A12210915.

العلاقة: https://portal.findresearcher.sdu.dk/da/publications/ac7b255c-e7d2-4dad-b7c1-c6e0b610e5aeTest

الإتاحة: https://portal.findresearcher.sdu.dk/da/publications/ac7b255c-e7d2-4dad-b7c1-c6e0b610e5aeTest
https://ugeskriftet.dk/dmj/reply-editorial-letter-limited-value-patient-reported-triage-algorithm-outpatient-epilepsyTest

المؤلفون: Spelman, Tim, Magyari, Melinda, Butzkueven, Helmut, Van Der Walt, Anneke, Vukusic, Sandra, Trojano, Maria, Iaffaldano, Pietro, Horáková, Dana, Drahota, Jirí, Pellegrini, Fabio, Hyde, Robert, Duquette, Pierre, Lechner-Scott, Jeannette, Sajedi, Seyed Aidin, Lalive, Patrice, Shaygannejad, Vahid, Ozakbas, Serkan, Eichau, Sara, Alroughani, Raed, Terzi, Murat, Girard, Marc, Kalincik, Tomas, Grand'Maison, Francois, Skibina, Olga, Khoury, Samia J., Yamout, Bassem, Sa, Maria Jose, Gerlach, Oliver, Blanco, Yolanda, Karabudak, Rana, Oreja-Guevara, Celia, Altintas, Ayse, Hughes, Stella, McCombe, Pamela, Ampapa, Radek, de Gans, Koen, McGuigan, Chris, Soysal, Aysun, Prevost, Julie, John, Nevin, Inshasi, Jihad, Stawiarz, Leszek, Manouchehrinia, Ali, Forsberg, Lars, Sellebjerg, Finn, Glaser, Anna, Pontieri, Luigi, Joensen, Hanna, Rasmussen, Peter Vestergaard, Sejbaek, Tobias, Poulsen, Mai Bang, Christensen, Jeppe Romme, Kant, Matthias, Stilund, Morten, Mathiesen, Henrik, Hillert, Jan

المصدر: Spelman , T , Magyari , M , Butzkueven , H , Van Der Walt , A , Vukusic , S , Trojano , M , Iaffaldano , P , Horáková , D , Drahota , J , Pellegrini , F , Hyde , R , Duquette , P , Lechner-Scott , J , Sajedi , S A , Lalive , P , Shaygannejad , V , Ozakbas , S , Eichau , S , Alroughani , R , Terzi , M , Girard , M , Kalincik , T , Grand'Maison , F , Skibina , O , ....

مصطلحات موضوعية: disease modifying treatment (DMT), disease registry, multiple sclerosis, real world evidence (RWE), treatment switching

الوصف: Background: Treatment switching is a common challenge and opportunity in real-world clinical practice. Increasing diversity in disease-modifying treatments (DMTs) has generated interest in the identification of reliable and robust predictors of treatment switching across different countries, DMTs, and time periods. Objective: The objective of this retrospective, observational study was to identify independent predictors of treatment switching in a population of relapsing-remitting MS (RRMS) patients in the Big Multiple Sclerosis Data Network of national clinical registries, including the Italian MS registry, the OFSEP of France, the Danish MS registry, the Swedish national MS registry, and the international MSBase Registry. Methods: In this cohort study, we merged information on 269,822 treatment episodes in 110,326 patients from 1997 to 2018 from five clinical registries. Patients were included in the final pooled analysis set if they had initiated at least one DMT during the relapsing-remitting MS (RRMS) stage. Patients not diagnosed with RRMS or RRMS patients not initiating DMT therapy during the RRMS phase were excluded from the analysis. The primary study outcome was treatment switching. A multilevel mixed-effects shared frailty time-to-event model was used to identify independent predictors of treatment switching. The contributing MS registry was included in the pooled analysis as a random effect. Results: Every one-point increase in the Expanded Disability Status Scale (EDSS) score at treatment start was associated with 1.08 times the rate of subsequent switching, adjusting for age, sex, and calendar year (adjusted hazard ratio [aHR] 1.08; 95% CI 1.07–1.08). Women were associated with 1.11 times the rate of switching relative to men (95% CI 1.08–1.14), whilst older age was also associated with an increased rate of treatment switching. DMTs started between 2007 and 2012 were associated with 2.48 times the rate of switching relative to DMTs that began between 1996 and 2006 (aHR 2.48; 95% CI 2.48–2.56). DMTs ...

وصف الملف: application/pdf

العلاقة: https://portal.findresearcher.sdu.dk/da/publications/d0ed5c7d-5622-4f26-a794-d16b0c08bc56Test

الإتاحة: https://doi.org/10.3389/fneur.2023.1274194Test
https://portal.findresearcher.sdu.dk/da/publications/d0ed5c7d-5622-4f26-a794-d16b0c08bc56Test
https://findresearcher.sdu.dk/ws/files/257032005/fneur-14-1274194.pdfTest

المؤلفون: Novak, Frederik, Bajwa, Hamza Mahmood, Coia, John Eugenio, Nilsson, Anna Christine, Nielsen, Christian, Holm, Dorte K, Østergaard, Kamilla, Hvidt, Mathilde Vilhelmine Miller, Byg, Keld-Erik, Johansen, Isik S, Mittl, Kristen, Rowles, William, Zamvil, Scott S, Bove, Riley, Sabatino, Joseph J, Sejbaek, Tobias

مصطلحات موضوعية: Multiple sclerosis

الوصف: Background Our study investigated the rate of breakthrough SARS-CoV-2 infection and clinical outcomes in a cohort of multiple sclerosis (MS) patients who were treated with the anti-CD20 monoclonal antibody (Ab), ocrelizumab, before first, second and third BNT162b2 mRNA vaccinations. To correlate clinical outcomes with the humoral and cellular response. Methods The study was a prospective non-randomised controlled multicentre trial observational study. Participants with a diagnosis of MS who were treated for at least 12 months with ocrelizumab prior to the first BNT162b2 mRNA vaccination were prospectively followed up from January 2021 to June 2022. Results Out of 54 participants, 32 (59.3%) developed a positive SARS-CoV-2 PCR test in the study period. Mild infection was observed in all infected participants. After the third vaccination, the non-infected participants had higher mean Ab levels compared to the infected participants (54.3 binding antibody unit (BAU)/mL vs 26.5 BAU/mL, p=0.030). The difference in reactivity between spike-specific CD4+ and CD8+ T lymphocytes in the two groups was not significant. Conclusion and relevance The study results demonstrate rates of 59% in breakthrough infections after the third SARS-CoV-2 mRNA vaccination in ocrelizumab-treated patients with MS, without resulting in critical disease courses. These findings suggest the need for continuous development of prophylactic treatments when proved important in the protection of severe breakthrough infection.

وصف الملف: text/html

العلاقة: http://jnnp.bmj.com/cgi/content/short/94/11/934Test; http://dx.doi.org/10.1136/jnnp-2022-330757Test

الإتاحة: https://doi.org/10.1136/jnnp-2022-330757Test
http://jnnp.bmj.com/cgi/content/short/94/11/934Test

المؤلفون: Novak, Frederik, Bajwa, Hamza Mahmood, Coia, John Eugenio, Nilsson, Anna Christine, Nielsen, Christian, Holm, Dorte K, Østergaard, Kamilla, Hvidt, Mathilde Vilhelmine Miller, Byg, Keld-Erik, Johansen, Isik S, Mittl, Kristen, Rowles, William, Zamvil, Scott S, Bove, Riley, Sabatino, Joseph J, Sejbaek, Tobias

مصطلحات موضوعية: Prevention, Neurodegenerative, Biotechnology, Immunization, Brain Disorders, Clinical Trials and Supportive Activities, Pneumonia & Influenza, Neurosciences, Vaccine Related, Infectious Diseases, Autoimmune Disease, Pneumonia, Clinical Research, Emerging Infectious Diseases, Lung, Multiple Sclerosis, Infection, Good Health and Well Being, IMMUNOLOGY, Medical and Health Sciences, Psychology and Cognitive Sciences, Neurology & Neurosurgery

الوصف: BackgroundOur study investigated the rate of breakthrough SARS-CoV-2 infection and clinical outcomes in a cohort of multiple sclerosis (MS) patients who were treated with the anti-CD20 monoclonal antibody (Ab), ocrelizumab, before first, second and third BNT162b2 mRNA vaccinations. To correlate clinical outcomes with the humoral and cellular response.MethodsThe study was a prospective non-randomised controlled multicentre trial observational study. Participants with a diagnosis of MS who were treated for at least 12 months with ocrelizumab prior to the first BNT162b2 mRNA vaccination were prospectively followed up from January 2021 to June 2022.ResultsOut of 54 participants, 32 (59.3%) developed a positive SARS-CoV-2 PCR test in the study period. Mild infection was observed in all infected participants. After the third vaccination, the non-infected participants had higher mean Ab levels compared to the infected participants (54.3 binding antibody unit (BAU)/mL vs 26.5 BAU/mL, p=0.030). The difference in reactivity between spike-specific CD4+ and CD8+ T lymphocytes in the two groups was not significant.Conclusion and relevanceThe study results demonstrate rates of 59% in breakthrough infections after the third SARS-CoV-2 mRNA vaccination in ocrelizumab-treated patients with MS, without resulting in critical disease courses. These findings suggest the need for continuous development of prophylactic treatments when proved important in the protection of severe breakthrough infection.

العلاقة: qt0mx935gf; https://escholarship.org/uc/item/0mx935gfTest

الإتاحة: https://escholarship.org/uc/item/0mx935gfTest